...
首页> 外文期刊>Expert opinion on therapeutic targets >Targeting angiotensin II type I receptors to reduce the risk of stroke in patients with hypertension.
【24h】

Targeting angiotensin II type I receptors to reduce the risk of stroke in patients with hypertension.

机译:靶向I型血管紧张素受体以降低高血压患者中风的风险。

获取原文
获取原文并翻译 | 示例

摘要

The incidence of stroke is rising among the elderly population. Hypertension is the single most important contributor to stroke, and hypertension treatment and control is the most important intervention to prevent it. Blood pressure reduction by any means will substantially reduce the risk of stroke. However, accumulating evidence indicates that angiotensin receptor blocker-based regimens may provide additional benefits in the prevention of stroke. This effect seems to be particularly prominent in high-risk patients and patients with isolated systolic hypertension. The pathophysiological mechanisms have not been clearly delineated, but favourable remodelling of the left atrium and reduction of the risk of atrial fibrillation has been suggested. In addition, blockade of the central AT1 receptors and stimulation of AT2 receptors and/or preferential reduction of central pressure by angiotensin receptor blockers may account for the beneficial protective effect.
机译:中老年人的中风发病率正在上升。高血压是导致中风的最重要因素,高血压的治疗和控制是预防中风的最重要干预措施。通过任何方式降低血压都将大大降低中风的风险。但是,越来越多的证据表明,基于血管紧张素受体阻滞剂的治疗方案可能在预防中风方面提供更多益处。在高危患者和单纯收缩期高血压患者中,这种作用似乎尤为突出。尚未明确其病理生理机制,但已建议对左心房进行良好的重塑并降低房颤的风险。另外,通过血管紧张素受体阻滞剂对中枢AT1受体的阻断和对AT2受体的刺激和/或中枢压力的优先降低可以解释有益的保护作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号